JP2020500562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500562A5 JP2020500562A5 JP2019551257A JP2019551257A JP2020500562A5 JP 2020500562 A5 JP2020500562 A5 JP 2020500562A5 JP 2019551257 A JP2019551257 A JP 2019551257A JP 2019551257 A JP2019551257 A JP 2019551257A JP 2020500562 A5 JP2020500562 A5 JP 2020500562A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- polynucleotide
- ltr
- virus
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430819P | 2016-12-06 | 2016-12-06 | |
| US62/430,819 | 2016-12-06 | ||
| PCT/US2017/064940 WO2018106821A1 (en) | 2016-12-06 | 2017-12-06 | Gene therapy for mucopolysaccharidosis, type ii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500562A JP2020500562A (ja) | 2020-01-16 |
| JP2020500562A5 true JP2020500562A5 (enExample) | 2021-01-21 |
Family
ID=62492351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551257A Pending JP2020500562A (ja) | 2016-12-06 | 2017-12-06 | ムコ多糖症ｉｉ型のための遺伝子治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200071721A1 (enExample) |
| EP (1) | EP3562937A4 (enExample) |
| JP (1) | JP2020500562A (enExample) |
| KR (1) | KR20190088554A (enExample) |
| CN (1) | CN110199028A (enExample) |
| AU (1) | AU2017370673A1 (enExample) |
| BR (1) | BR112019011590A2 (enExample) |
| CA (1) | CA3046080A1 (enExample) |
| IL (1) | IL267060A (enExample) |
| MA (1) | MA47173A (enExample) |
| MX (1) | MX2019006551A (enExample) |
| RU (1) | RU2019120663A (enExample) |
| WO (1) | WO2018106821A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109641063B (zh) | 2016-04-20 | 2022-11-15 | 能源环境和技术研究中心O.A., M.P. | 用于增强pklr的基因表达的组合物和方法 |
| SG11202002263TA (en) | 2017-10-16 | 2020-04-29 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency |
| JP7576754B2 (ja) | 2018-04-11 | 2024-11-01 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | 幹細胞移植のための組成物および方法 |
| MX2021001292A (es) * | 2018-07-30 | 2021-07-15 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Metodos para la modificacion genica de celulas hematopoyeticas. |
| WO2022212616A1 (en) * | 2021-04-01 | 2022-10-06 | The University Of North Carolina At Chapel Hill | Aav-ids vectors for treatment of mucopolysaccharidosis ii |
| WO2024233287A1 (en) * | 2023-05-05 | 2024-11-14 | The Regents Of The University Of California | Viral vectors for cell therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| US20110294114A1 (en) * | 2009-12-04 | 2011-12-01 | Cincinnati Children's Hospital Medical Center | Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells |
| AU2012267512B2 (en) * | 2011-06-10 | 2014-11-20 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
| US9695443B2 (en) * | 2012-05-25 | 2017-07-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Vector for the selective silencing of a gene in astrocytes |
| WO2014201252A2 (en) * | 2013-06-13 | 2014-12-18 | Shire Human Genetic Therapies, Inc. | Messenger rna based viral production |
-
2017
- 2017-12-06 AU AU2017370673A patent/AU2017370673A1/en not_active Abandoned
- 2017-12-06 US US16/466,123 patent/US20200071721A1/en not_active Abandoned
- 2017-12-06 BR BR112019011590A patent/BR112019011590A2/pt not_active IP Right Cessation
- 2017-12-06 JP JP2019551257A patent/JP2020500562A/ja active Pending
- 2017-12-06 RU RU2019120663A patent/RU2019120663A/ru not_active Application Discontinuation
- 2017-12-06 CN CN201780083277.7A patent/CN110199028A/zh active Pending
- 2017-12-06 WO PCT/US2017/064940 patent/WO2018106821A1/en not_active Ceased
- 2017-12-06 CA CA3046080A patent/CA3046080A1/en not_active Abandoned
- 2017-12-06 MX MX2019006551A patent/MX2019006551A/es unknown
- 2017-12-06 EP EP17878786.7A patent/EP3562937A4/en not_active Withdrawn
- 2017-12-06 MA MA047173A patent/MA47173A/fr unknown
- 2017-12-06 KR KR1020197019345A patent/KR20190088554A/ko not_active Ceased
-
2019
- 2019-06-03 IL IL267060A patent/IL267060A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536484A5 (enExample) | ||
| JP2019517281A5 (enExample) | ||
| RU2019120721A (ru) | Генная терапия для лечения мукополисахаридоза i типа | |
| RU2019120663A (ru) | Генная терапия для лечения мукополисахаридоза ii типа | |
| RU2021103425A (ru) | Композиции, повышающие число копий вектора (чкв), и способы их применения | |
| Quinonez et al. | Lentiviral vectors for gene delivery into cells | |
| Hirsch et al. | The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein | |
| JP2014519335A5 (enExample) | ||
| Ramezani et al. | Overview of the HIV‐1 lentiviral vector system | |
| JP4992032B2 (ja) | レトロウイルスベクター | |
| US20170362607A1 (en) | Use of non-subtype b gag proteins for lentiviral packaging | |
| Liu et al. | HIV-1-based lentiviral vectors | |
| Oda et al. | Molecular cloning, complete nucleotide sequence, and gene structure of the provirus genome of a retrovirus produced in a human lymphoblastoid cell line | |
| Perez et al. | Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor | |
| Browning et al. | Sequences within the gag gene of feline immunodeficiency virus (FIV) are important for efficient RNA encapsidation | |
| WO2003080846A1 (fr) | Procede de production de vecteurs lentiviraux a haut titre | |
| Trono | Lentiviral vectors | |
| Federico | From lentiviruses to lentivirus vectors | |
| Nègre et al. | Vectors derived from simian immunodeficiency virus (SIV) | |
| WO2005056057A1 (en) | Minimal lentiviral vector system | |
| Pandya et al. | Lentivirus and foamy virus vectors: novel gene therapy tools | |
| Curran et al. | Nonprimate lentiviral vectors | |
| Schüle et al. | Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj | |
| Wolkowicz et al. | Lentiviral vectors for the delivery of DNA into mammalian cells | |
| Mukherjee et al. | A HIV-2-based self-inactivating vector for enhanced gene transduction |